...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Medical Virology >Outcome in partial early virologic responders to combination therapy with peginterferon and ribavirin in patients infected with hepatitis C virus genotype 1b
【24h】

Outcome in partial early virologic responders to combination therapy with peginterferon and ribavirin in patients infected with hepatitis C virus genotype 1b

机译：丙型肝炎病毒基因型1b感染患者接受聚乙二醇干扰素联合利巴韦林联合治疗的部分早期病毒学应答结果

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The course and outcome in patients infected with hepatitis C virus (HCV) genotype 1b with partial early virologic response during combination therapy with peginterferon and ribavirin, in whom serum HCV RNA is detectable but has decreased by more than 2 log10 12 weeks after the start of the therapy, has not been elucidated sufficiently. The outcome in this group of patients was investigated. Serum HCV RNA levels was measured every 4 weeks in 149 patients with HCV genotype 1b infection who underwent combination therapy for 48 weeks. In patients with partial early virologic response, the time point when serum HCV RNA became undetectable as well as the final virologic response to treatment was determined. Sixty-three patients (42.3%) had partial early virologic response. The time when serum HCV RNA became undetectable ranged from 16 to 48 weeks after the start of therapy. Serum HCV RNA remained detectable in 17 patients. The rates of sustained virologic response decreased with the delay of the time when serum HCV RNA became undetectable; sustained virologic responder was not found in patients in whom HCV RNA was still detectable at 24 weeks after the start of treatment. The degree of decrease in serum HCV RNA levels at 12 weeks corresponded to the rate of sustained virologic response in partial early virologic responders. The outcome of partial early virologic responders varied greatly, and close monitoring of serum HCV RNA is required for predicting the outcome of treatment in these patients. J. Med. Virol. 83:101–107, 2011. © 2010 Wiley-Liss, Inc.
机译：在接受聚乙二醇干扰素和利巴韦林联合治疗期间感染了1b型丙型肝炎病毒（HCV）基因型且部分早期病毒学应答的患者的病程和预后，其中血清HCV RNA可以检测到，但在开始使用后12周下降了2 log10以上。该疗法尚未得到充分阐明。研究了这组患者的结局。每149名HCV基因型1b感染患者接受联合治疗48周后，每4周测量一次血清HCV RNA水平。在具有部分早期病毒学应答的患者中，确定了血清HCV RNA变得不可检测的时间点以及对治疗的最终病毒学应答。六十三名患者（42.3％）具有部分早期病毒学应答。血清HCV RNA检测不到的时间为治疗开始后16至48周。血清HCV RNA仍可检测到17例患者。随着无法检测到血清HCV RNA的时间延迟，持续病毒学应答率降低；在开始治疗后24周仍可检测到HCV RNA的患者中未发现持续的病毒学应答者。 12周时血清HCV RNA水平下降的程度与部分早期病毒学应答者中持续的病毒学应答率相对应。部分早期病毒学应答者的结果差异很大，需要密切监测血清HCV RNA才能预测这些患者的治疗结果。 J. Med。病毒83：101–107，2011.©2010 Wiley-Liss，Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号